Home » Topics » Nephrology, BioWorld Science

Nephrology, BioWorld Science
RSS

Achillion reports preliminary data from phase II study of ACH-4471 in C3G

Nov. 15, 2017

TP-0469711 demonstrates promising activity as a new therapeutic for hyperphosphatemia

Nov. 14, 2017

Novel antibody against TGF-beta1 shows efficacy without cardiotoxicity in fibrosis model

Nov. 14, 2017

Wound healing improved with SNF-472 in hemodialysis patients with calciphylaxis

Nov. 13, 2017

FDA accepts Otsuka's resubmitted NDA for tolvaptan

Nov. 10, 2017

FDA approves Keryx's Auryxia in new indication

Nov. 8, 2017

FDA gives orphan status to Achillion's ACH-4471 for PNH

Nov. 8, 2017

Klotho Therapeutics announces series A financing to advance patent pending version of Klotho

Nov. 7, 2017

Ono Pharmaceutical divulges novel voltage-gated channel activators

Nov. 6, 2017

VS-505 effective and well tolerated hyperphosphatemia treatment for hemodialysis patients

Nov. 3, 2017

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 15, 2026.
Microbiota modulates the antidepressant effects of GLP-1 analogues
BioWorld Science
Liraglutide, a glucagon-like peptide 1 (GLP-1) receptor agonist used in diabetes and obesity, could alleviate depression through a pathway that does not depend on...
Ethyreal launches to treat the underlying cause of Graves’, TED
BioWorld
Ethyreal Bio Inc. has come out of stealth mode in order to disclose preclinical data for ETHY-001, its monoclonal antibody targeting thyroid stimulating hormone...
EHA 2026: With new lenses, a changing view on pediatric cancers
BioWorld
In the most simplistic view, adult cancers occur because “immature cells are exposed to mutagens, accumulate mutations, and across life ultimately transform into...
Enliven’s phase I CML data Enable phase III with BCR/ABL1 bid
BioWorld
Tolerability is a key factor in the appeal of Enliven Therapeutics Inc.’s ELVN-001 for previously treated chronic myeloid leukemia (CML), which yielded positive...